CCS

Across TCGA pan-cancer cohorts, CCS mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated CCS data layer compared with 20 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher CCS mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated CCS expression acts as an unfavorable survival marker, although some lineages such as CCRCC and PDAC show a favorable association.

LUAD, CCRCC, and HNSC are the cancer types where CCS mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Tertile	III,IV	0.514	0.976	.008	21	view →
CCRCC	DFS	Quartile	All	1.000	0.508	.006	15	view →
HNSC	OS	Tertile	II,III,IV	0.931	1.000	.018	11	view →
PDAC	DFS	Median	II,III,IV	0.828	0.636	.008	8	view →
OV	DFS	Median	All	0.628	0.929	.023	4	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

CCS–LUAD (DFS)

Open the LUAD breakdown →